ETON PHARMACEUTICALS INC (ETON)
US29772L1089 - Common Stock
We assign a fundamental rating of 3 out of 10 to ETON. ETON was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of ETON is average, but there are quite some concerns on its profitability. ETON has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ETON has reported negative net income.
ETON had a positive operating cash flow in the past year.
In the past 5 years ETON always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ETON reported negative operating cash flow in multiple years.
1.2 Ratios
ETON has a Return On Assets of -2.95%. This is in the better half of the industry: ETON outperforms 78.46% of its industry peers.
With an excellent Return On Equity value of -6.05%, ETON belongs to the best of the industry, outperforming 81.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.95% | ||
| ROE | -6.05% | ||
| ROIC | N/A |
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ETON has a Gross Margin of 66.56%. This is in the better half of the industry: ETON outperforms 70.26% of its industry peers.
ETON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ETON has been increased compared to 1 year ago.
Compared to 5 years ago, ETON has more shares outstanding
ETON has a better debt/assets ratio than last year.
2.2 Solvency
ETON has an Altman-Z score of 0.24. This is a bad value and indicates that ETON is not financially healthy and even has some risk of bankruptcy.
ETON has a Altman-Z score of 0.24. This is comparable to the rest of the industry: ETON outperforms 52.82% of its industry peers.
There is no outstanding debt for ETON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.89 | ||
| Altman-Z | 0.24 |
ROIC/WACCN/A
WACC9.25%
2.3 Liquidity
A Current Ratio of 1.65 indicates that ETON should not have too much problems paying its short term obligations.
ETON has a Current ratio of 1.65. This is in the lower half of the industry: ETON underperforms 72.82% of its industry peers.
A Quick Ratio of 1.60 indicates that ETON should not have too much problems paying its short term obligations.
ETON has a Quick ratio of 1.60. This is in the lower half of the industry: ETON underperforms 67.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.6 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 82.86% over the past year.
ETON shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.84%.
ETON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 824.84% yearly.
EPS 1Y (TTM)82.86%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-325%
Revenue 1Y (TTM)48.84%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Revenue growth Q2Q-13.96%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y542%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year29.38%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ETON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 14.14, which indicates a correct valuation of ETON.
87.18% of the companies in the same industry are more expensive than ETON, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.58. ETON is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 14.14 |
4.2 Price Multiples
86.15% of the companies in the same industry are more expensive than ETON, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.95 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ETON's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ETON!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ETON PHARMACEUTICALS INC
NASDAQ:ETON (5/6/2024, 7:00:02 PM)
After market: 3.76 +0.01 (+0.27%)3.75
+0.04 (+1.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap96.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 14.14 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.95% | ||
| ROE | -6.05% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.56% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)82.86%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y542%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)48.84%
Revenue growth 3Y824.84%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y